Efficacy and safety of the subcutaneous Methotrexate in patients with Rheumatoid arthritis who can not tolerate oral MTX (Metojective study) - Efficacy and safety of the subcutaneous Methotrexate in patients with Rheumatoid arthritis who can not tolerate oral MTX

Seirei Hamamatsu General Hospital0 个研究点目标入组 60 人开始时间: 2023年10月1日最近更新: 2024年5月27日

适应症

试验速览

暂无简介。

•1) Patients under 18 years of age 2) Patients with drug allergy to MTX 3) Patients with serious liver disease (Grade 3 or higher in CTCAE Ver5.0) 4) Patients with serious renal disease (eGFR <30) 5) Patients with severe interstitial pneumonia 6) Patients with hematologic malignancies 7) Patients with pleural effusion or ascites 8) Patients with active tuberculosis or other infectious diseases 9) Women who are pregnant or may become pregnant 10) Women who are breast-feeding 11) Patients with cognitive impairment and inability to maintain adherence 12) Other patients who are deemed inappropriate as research subjects by the principal investigator or research coordinator. 12) Other patients deemed inappropriate as research subjects by the principal investigator or principal investigator's assistant.

发起方